The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

September 11, 2025

Primary Completion Date

August 12, 2028

Study Completion Date

November 4, 2028

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

626

626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.

DRUG

626

626 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

NCT07185269 - The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE | Biotech Hunter | Biotech Hunter